These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764 [TBL] [Abstract][Full Text] [Related]
7. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification. Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585 [TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Nomogram for Differentiating Combined Hepatocellular Cholangiocarcinoma From Intrahepatic Cholangiocarcinoma. Wang T; Wang W; Zhang J; Yang X; Shen S; Wang W Front Oncol; 2020; 10():598433. PubMed ID: 33363028 [TBL] [Abstract][Full Text] [Related]
10. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
11. Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know. Cutolo C; Dell'Aversana F; Fusco R; Grazzini G; Chiti G; Simonetti I; Bruno F; Palumbo P; Pierpaoli L; Valeri T; Izzo F; Giovagnoni A; Grassi R; Miele V; Barile A; Granata V Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453938 [TBL] [Abstract][Full Text] [Related]
12. Primary liver cancer classification from routine tumour biopsy using weakly supervised deep learning. Beaufrère A; Ouzir N; Zafar PE; Laurent-Bellue A; Albuquerque M; Lubuela G; Grégory J; Guettier C; Mondet K; Pesquet JC; Paradis V JHEP Rep; 2024 Mar; 6(3):101008. PubMed ID: 38379584 [TBL] [Abstract][Full Text] [Related]
13. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787 [No Abstract] [Full Text] [Related]
14. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274 [TBL] [Abstract][Full Text] [Related]
15. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018. Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040 [TBL] [Abstract][Full Text] [Related]